Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.US-based biotechnology company Meissa Vaccines has started preclinical studies and manufacturing of its intranasal, live attenuated vaccine (LAV) candidate MV-014-210 against Covid-19.
MV-014-210, formulated for a single adjuvant-free dose, will be assessed for its ability to trigger immunity and protect against SARS-CoV-2, the coronavirus that causes Covid-19.
Based on the company’s codon deoptimized RSV vaccine platform, the Covid-19 vaccine candidate is obtained by altering RSV LAV candidate MV-012-968.